Johnson & Johnson (“J&J”) announced on November 1, 2022, that it will acquire Abiomed for an upfront payment of $380.00 per share in cash, which equates to about $16.6 billion. The acquisition is expected to be completed in the first quarter of 2023. According to reports, after the acquisition, Abiomed “will operate as a standalone business within J&J within Johnson & Johnson MedTech, becoming one of the company’s dozen ‘priority platforms,’ defined by annual sales of at least $1 billion.”
Joaquin Duato, Chief Executive Officer of Johnson & Johnson, stated that “[t]he addition of Abiomed is an important step in the execution of our strategic priorities and our vision for the new Johnson & Johnson focused on Pharmaceutical and MedTech,” and he further stated the acquisition will continue to enhance J&J’s “position in MedTech by entering high-growth segments. The addition of Abiomed provides a strategic platform to advance breakthrough treatments in cardiovascular disease and helps more patients around the world while driving value for our shareholders.” The acquisition follows reports earlier this year that J&J intended to “get active on the medtech M&A front.”
Abiomed was founded in 1981 “for the purpose of developing the world’s first artificial heart. ” Abiomed currently makes the Impella heart pump, which is “a support system of percutaneous catheter-based technology offering hemodynamic support to the heart.” Abiomed also offers the Breathe OXY-1 System, which is a “cardiopulmonary support system with an integrated oxygen concentrator.” Last year, Abiomed acquired the start-up preCARDIA and its catheter technology. Recently, “Abiomed reported revenue of $266 million, up 7% and up 11% in constant currency year over year, the seventh consecutive quarter the company posted double-digit revenue growth in constant currency.”
The press release may be accessed here.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- Platoblockchain. Web3 Metaverse Intelligence. Knowledge Amplified. Access Here.
- Source: http://knobbemedical.com/medicaldeviceblog/article/jj-acquires-abiomed-for-16-6-billion/?utm_source=rss&utm_medium=rss&utm_campaign=jj-acquires-abiomed-for-16-6-billion
- $1 billion
- 1
- 2022
- a
- About
- accessed
- According
- acquire
- Acquires
- acquisition
- active
- addition
- advance
- After
- and
- annual
- around
- artificial
- becoming
- Billion
- breakthrough
- business
- Cardiovascular Disease
- Cash
- chief
- chief executive officer
- clear
- company
- Company’s
- consecutive
- constant
- continue
- Currency
- Currently
- developing
- Disease
- dozen
- driving
- Earlier
- equates
- Ether (ETH)
- execution
- executive
- Executive Officer
- First
- focused
- follows
- front
- further
- Growth
- Heart
- helps
- high-growth
- Horizontal
- HTTPS
- important
- in
- integrated
- IT
- Johnson
- Last
- Last Year
- M&A
- MAKES
- medium
- Medtech
- million
- more
- New
- November
- offering
- Offers
- Officer
- ONE
- operate
- Oxygen
- patients
- payment
- Pharmaceutical
- platform
- Platforms
- plato
- Plato Data Intelligence
- PlatoData
- posted
- press
- Press Release
- provides
- pump
- purpose
- Quarter
- release
- Reported
- Reports
- revenue
- revenue growth
- sales
- segments
- Share
- Shareholders
- standalone
- Start-up
- stated
- Step
- Strategic
- support
- system
- Technology
- The
- the world
- to
- true
- value
- vision
- which
- while
- will
- within
- world
- world’s
- year
- zephyrnet